Taken together, ROS1-rearranged patients represent a unique subgroup of NSCLC patients, with a relatively good prognosis, a remarkable good outcome under different regimens of chemotherapy and dramatic responses under crizotinib. Here, ROS1 is linked to non-small cell lung carcinoma.